|
gptkbp:instanceOf
|
gptkb:Corticosteroid
gptkb:synthetic_glucocorticoid
|
|
gptkbp:ATCCode
|
R03BA05
R01AD08
|
|
gptkbp:bioavailability
|
10-30% (inhaled)
less than 1% (oral)
|
|
gptkbp:brand
|
gptkb:Cutivate
gptkb:Flixotide
gptkb:Flonase
gptkb:Veramyst
gptkb:Flovent
|
|
gptkbp:CASNumber
|
80474-14-2
|
|
gptkbp:chemicalClass
|
corticosteroid ester
|
|
gptkbp:contraindication
|
hypersensitivity
untreated local infection
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
7.8 hours
|
|
gptkbp:hasMolecularFormula
|
C25H31F3O5S
|
|
gptkbp:introducedIn
|
1990
|
|
gptkbp:KEGGID
|
D00357
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
glucocorticoid receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
91%
|
|
gptkbp:PubChem_CID
|
39137
444036
CHEMBL1200698
DB00588
|
|
gptkbp:riskFactor
|
adrenal suppression (with high doses)
growth suppression in children (rare)
systemic corticosteroid effects (rare)
|
|
gptkbp:routeOfAdministration
|
gptkb:nasal_spray
topical
inhalation
|
|
gptkbp:sideEffect
|
gptkb:oral_candidiasis
headache
hoarseness
throat irritation
nosebleed
|
|
gptkbp:UNII
|
0J48LPH2TH
|
|
gptkbp:usedFor
|
asthma
chronic obstructive pulmonary disease
allergic rhinitis
nasal polyps
|
|
gptkbp:bfsParent
|
gptkb:Advair
gptkb:Flovent
gptkb:Seretide
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fluticasone propionate
|